SCHEMBL628338

SCHEMBL628338

[CH2]CCN(CC)C(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL736392 0.84
SCHEMBL12790551 0.82 FDPS (0.33)
SCHEMBL6976416 0.77 MMP1 (0.30)
SCHEMBL12790550 0.77 FDPS (0.31)
SCHEMBL1162974 0.77
SCHEMBL737157 0.77
SCHEMBL20811 0.75
SCHEMBL4379736 0.74 MEN1 (0.35)
SCHEMBL23071771 0.72
SCHEMBL12860961 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11607465-B2 Uses of labeled HSP90 inhibitors SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2023-03-21 US claimed
US-20210138091-A1 USES OF LABELED HSP90 INHIBITORS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH 2021-05-13 US claimed
EP-3709022-A1 USES OF LABELED HSP90 INHIBITORS Sloan-Kettering Institute for Cancer Research (US) 2020-09-16 EP claimed
CN-106083855-B Purine derivatives useful as Hsp90 inhibitors 斯隆-凯特林癌症研究院 2020-04-10 CN claimed
EP-3208615-B1 USES OF LABELED HSP90 INHIBITORS SLOAN KETTERING INST CANCER RES (US) 2019-10-09 EP claimed
US-10336757-B2 Treatment of neurodegenerative diseases through inhibition of HSP90 SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2019-07-02 US claimed
US-10201623-B2 HSP90-targeted cardiac imaging and therapy MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2019-02-12 US claimed
US-10172863-B2 Purine derivatives useful as HSP90 inhibitors SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2019-01-08 US claimed
CN-106083855-A Purine derivative as Hsp90 inhibitor 斯隆-凯特林癌症研究院 2016-11-09 CN claimed
US-20160310497-A1 PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH 2016-10-27 US claimed
US-9328114-B2 Hsp90 inhibitors SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2016-05-03 US claimed
US-20140378452-A1 Treatment of Neurodegenerative Diseases Through Inhibition of HSP90 NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2014-12-25 US claimed
WO-2012021796-A2 NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION S&T GLOBAL, INC. (US) 2012-02-16 WO claimed
US-20090298857-A1 Treatment of Neurodegenerative Diseases Through Inhibition of HSP90 SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2009-12-03 US claimed
EP-2034839-A2 TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 Sloan-Kettering Institute For Cancer Research (US) 2009-03-18 EP claimed
WO-2008005937-A2 TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2008-01-10 WO claimed
US-20240158397-A1 TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2024-05-16 US disclosed
US-20240058482-A1 USES OF LABELED HSP90 INHIBITORS SLOAN KETTERING INST CANCER RES (US) 2024-02-22 US disclosed
US-5981557-A HAVING IMPROVING EFFECTS ON THE DYSMOTILITY IN THE GASTROINTESTINAL TRACT ZERIA PHARMACEUTICAL CO., LTD. (JP) 1999-11-09 US disclosed
EP-0870765-A1 AMINOTHIAZOLE DERIVATIVES, DRUG CONTAINING THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE COMPOUNDS ZERIA PHARMACEUTICAL CO., LTD. (JP) 1998-10-14 EP disclosed